RxDoctor Payments Data

Aslam Loya, MD

Internal Medicine · Houston, TXNPI 1700878816

Payments from drug & device makers

$30,525in general payments, 2019–2025

Across 64 payments — averaging $476.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$15K
  • AstraZeneca$12K
  • Ironwood Pharmaceuticals, Inc$3K
  • Amarin Pharma, Inc.$177
  • GSK$91
  • Astellas Pharma US Inc$80
  • plus $281 from 11 others

What the payments were for

  • Food & beverage$46771%
  • Education$19129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$30,525 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$103,003
Medicare patients
113
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$103,294
FarxigaDapagliflozin Propanediol63$71,832
JardianceEmpagliflozin46$58,510
EliquisApixaban38$49,445
JanumetSitagliptin Phos/Metformin Hcl44$41,645
RybelsusSemaglutide11$29,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$27,755
JanuviaSitagliptin Phosphate23$20,770
MyrbetriqMirabegron20$19,375
Tresiba Flextouch U-200Insulin Degludec24$16,036
Levemir FlexpenInsulin Detemir21$14,751
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$12,709
Atorvastatin Calcium711$7,358
Olmesartan Medoxomil160$6,736
Humalog Kwikpen U-100Insulin Lispro11$4,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$69$132,78588 claims
AstraZenecaFarxiga$12,046$71,83263 claims
MerckJanumet, Januvia$12$62,41667 claims
PfizerEliquis$38$49,44538 claims
GSKTrelegy Ellipta$91$27,75516 claims
Astellas Pharma US IncMyrbetriq$80$19,37520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →